Sibeprenlimab (Voyxact) Stabilizes Kidney Function in IgAN

📅 04/08/2026 14:51 📰 hcplive 👁️ 3 lectures 🌍 États-Unis 📂 Santé

Sibeprenlimab (Voyxact) achieves KDIGO goal, stabilizing eGFR decline in IgA nephropathy at 2-year Phase 3 VISIONARY readout.